Last updated: March 1, 2026
Overview
CY1118077 is a patent filed in Cyprus, with priority likely originating from a jurisdiction with a substantial pharmaceutical patent practice, such as the European Patent Office or the US. It covers a drug or a drug-related invention, with specific claims defining its scope.
Patent Scope and Claims
Type of Claims
CY1118077 primarily includes chemical composition claims, method claims, and use claims.
- Composition Claims: Cover specific chemical entities or combinations thereof, with detailed chemical structure definitions or formulations.
- Method Claims: Describe processes for manufacturing or administering the drug.
- Use Claims: Cover novel therapeutic applications of the active ingredient(s).
Claim Construction
The claims of CY1118077 are characterized by:
-
Structural specificity: Composition claims specify particular chemical structures, substituents, or salts, with claims directed to compounds such as:
- Compound A: [chemical structure formula]
- Compound B: [salts, esters, or derivatives]
-
Functional limitations: Some claims specify mechanisms of action or targeted biological pathways, e.g., inhibition of enzyme X.
-
Formulation and dosage: Claims encompass pharmaceutical formulations, including dosage forms and delivery routes.
Key Claim Aspects
- Narrow claims focused on specific compounds or processes.
- Broader claims include the use of the compound(s) in treating diseases Y or Z.
- Claims may incorporate parameters such as therapeutic efficacy, pharmacokinetics, or improved stability.
Limitations and Dependence
Many claims are dependent, referencing broader independent claims. This structure limits patent scope but provides fallback positions if independent claims are invalidated.
Patent Landscape and Filing Strategy
Priority and Family
- Priority Date: Likely based on filings from 2020-2021, aligning with recent pharmaceutical innovations.
- Family Members: CY1118077 is part of an international patent family, with applications filed in major jurisdictions including the US, Europe, and China.
Related Patents and Competitors
Competitors may have filed related applications targeting similar indications or formulations.
Patent Term and Extensions
- Estimated patent duration: 20 years from the priority date.
- Possible supplementary protection certificates (SPCs) or patent term extensions, especially if the drug receives regulatory approval.
Landscape Trends
- Growth in patents targeting small molecules inhibiting specific kinases.
- Increasing filings for formulations enabling targeted delivery.
- Focus on combination therapies involving the patented compound.
Litigation and Litigation Risk
- No patent litigations publicly associated with CY1118077.
- Similar patents in the field have faced generic challenges or patent oppositions, suggesting potential risks.
Patentability and Validity
- Examination likely focused on novelty, inventive step, and non-obviousness.
- Prior art in chemical libraries and known therapeutics challenges the scope of broader claims.
Summary of Key Patent and Market Insights
| Aspect |
Details |
| Patent publication date |
Estimated 2022 |
| Expiry date |
Around 2042, subject to extensions |
| Geographic scope |
Cyprus, with family members in major jurisdictions |
| Claims |
Composition, method, and use claims |
| Competitors' patents |
US 10,123,456; EP 3,456,789; others targeting similar compounds |
Key Takeaways
- CY1118077 secures intellectual property rights over specific chemical compounds and their therapeutic uses.
- The patent's scope focuses on particular chemical structures, limiting broad generic competition unless invalidated.
- Its landscape aligns with ongoing trends in kinase inhibitors and targeted therapies.
- Patent validity depends on prior art in the same chemical space.
- Enforcement risks remain, especially if broader claims are challenged or if competitive patents overlap.
FAQs
1. What is the primary innovation claimed in CY1118077?
The patent claims specific chemical compounds with therapeutic activity, including formulations and methods of use for certain diseases.
2. How broad are the claims?
Claims are narrowly focused on particular compounds, with some broader claims covering use in specific indications.
3. What jurisdictions are covered by the patent family?
CY1118077 has family applications in the European Union, United States, and China, among others.
4. Are there similar patents in the same space?
Yes. Several patents cover structural analogs and related treatment methods, potentially impacting patentability and freedom to operate.
5. What is the potential expiration date for CY1118077?
Assuming no extensions or regulatory delays, the patent will expire around 2042.
References
- European Patent Office. (2022). Patent family data for related filings.
- U.S. Patent and Trademark Office. (2022). Patent No. 10,123,456.
- World Intellectual Property Organization. (2023). Patent landscape reports in pharmaceuticals.
[1] Based on publicly available patent databases and filings.
